Markets:

Overview

News

Currencies

International

Treasuries

Theravance Biopharma, Inc. - Ordinary Shares (NQ:TBPH)

18.74 -0.14 (-0.74%)

Streaming Delayed Price Updated: 9:32 AM EST, Jan 8, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Theravance Biopharma, Inc. - Ordinary Shares

< Previous 1 2 3 4 5 6 Next >

A Preview Of Theravance Biopharma's Earnings ↗

February 23, 2024

Via Benzinga

Logitech Posts Q3 Results, Joins Coinbase And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session ↗

January 23, 2024

U.S. stock futures were mostly lower this morning, with the Dow futures falling around 20 points on Tuesday.

Via Benzinga

Topics Stocks

Why Applied Therapeutics Shares Are Trading Lower By Over 35%? Here Are Other Stocks Moving In Friday's Mid-Day Session ↗

January 05, 2024

Shares of Applied Therapeutics, Inc.

Via Benzinga

Why Is Lung Disease Focused Theravance Biopharma Stock Trading Lower Today? ↗

January 05, 2024

Theravance Biopharma Inc (NASDAQ: TBPH) announced results from the Phase 4 PIFR-2 study of Yupelri (revefenacin) inhalation solution, the only once-daily, nebulized long-acting muscarinic antagonist...

Via Benzinga

Theravance Biopharma Earnings Preview ↗

August 04, 2023

Via Benzinga

Earnings Preview: Theravance Biopharma ↗

February 24, 2023

Via Benzinga

12 Health Care Stocks Moving In Friday's Pre-Market Session ↗

January 05, 2024

Via Benzinga

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday ↗

January 05, 2024

Pre-market stock movers are worth checking on Friday as we lay out all of the biggest stories worth keeping tabs on this morning!

Via InvestorPlace

Franklin Covey Shares Fall After Q1 Results, Joins Theravance Biopharma, Voyager Therapeutics And Other Big Stocks Moving Lower In Friday's Pre-Market Session ↗

January 05, 2024

U.S. stock futures were lower this morning, with the Dow Jones futures falling around 50 points on Friday.

Via Benzinga

Topics Stocks

7 Short-Squeeze Stocks That Are Screaming for Speculation ↗

December 24, 2023

If you like to march to your own beat even against high pressure, these short-squeeze stocks could be right for you.

Via InvestorPlace

Week In Review: Legend Partners DLL3 CAR-T Candidate With Novartis In $1.2 Billion Deal ↗

November 18, 2023

Legend Biotech partnered its DLL3 CAR-T candidates to Novartis in a $1.2 billion agreement, with $100 million offered upfront. Novartis will own worldwide rights to develop, manufacture, and...

Via Talk Markets

Roblox, Under Armour, GoPro, Nuvei And Other Big Stocks Moving Higher On Wednesday ↗

November 08, 2023

U.S. stocks traded mostly lower, with the Nasdaq Composite falling around 20 points on Wednesday. Here are some big stocks recording gains in today’s session.

Via Benzinga

Topics Stocks

Stocks That Hit 52-Week Lows On Friday ↗

September 29, 2023

Friday's session saw 112 companies set new 52-week lows.

Via Benzinga

Earnings Scheduled For November 7, 2023 ↗

November 07, 2023

Companies Reporting Before The Bell • CorEnergy Infr Tr (NYSE:CORR) is estimated to report earnings for its third quarter.

Via Benzinga

Stocks That Hit 52-Week Lows On Friday ↗

September 15, 2023

Friday's session saw 169 companies set new 52-week lows.

Via Benzinga

Takeda Moves Out From Licensing Agreement With Theravance Biopharma ↗

May 11, 2023

In its Q1 earnings release, Takeda Pharmaceutical Co Ltd (NYSE: TAK) said it agreed to discontinue further development of TAK-954 for post-operative gastrointestinal dysfunction and the parties'...

Via Benzinga

Earnings Scheduled For May 8, 2023 ↗

May 08, 2023

Companies Reporting Before The Bell • HNI (NYSE:HNI) is likely to report quarterly loss at $0.03 per share on revenue of $462.26 million.

Via Benzinga

Tiziana Life Sciences Has Only Fully Human Anti-CD3 mAB In Clinical Studies, Could Be Poised To Improve Care For Patients With Severe Multiple Sclerosis ↗

April 19, 2023

Tiziana Life Sciences (NASDAQ: TLSA), a London-based biotechnology company, is developing a first-in-class drug, Foralumab. Foralumab is the only fully human anti-CD3 monoclonal antibody (mAb) at the...

Via Benzinga

Theravance Biopharma Finally Shelves Failed JAK Inhibitor Program, Lays Off Staff ↗

February 28, 2023

Via Benzinga

Irenic Sends Letter to Theravance Biopharma Regarding the Urgent Need for a Governance Overhaul, Capital Return and Strategic Review

February 27, 2023

From Irenic Capital Management, LP

Via Business Wire

Target To Rally 29%? Plus This Analyst Predicts $245 For IQVIA Holdings ↗

November 17, 2022

Piper Sandler boosted the price target on Target Corporation (NYSE: TGT) from $190 to $200. Target shares fell 13.1% to close at $155.47 on Wednesday.

Via Benzinga

A Preview Of Theravance Biopharma's Earnings ↗

November 04, 2022

Theravance Biopharma (NASDAQ:TBPH) is set to give its latest quarterly earnings report on Monday, 2022-11-07. Here's what investors need to know before the announcement. Analysts estimate that...

Via Benzinga

Earnings Scheduled For February 27, 2023 ↗

February 27, 2023

Companies Reporting Before The Bell • Kosmos Energy (NYSE:KOS) is projected to report quarterly earnings at $0.14 per share on revenue of $505.61 million.

Via Benzinga

Earnings Scheduled For November 7, 2022 ↗

November 07, 2022

Companies Reporting Before The Bell • NAPCO Security Techs (NASDAQ:NSSC) is expected to report quarterly earnings at $0.13 per share on revenue of $36.34 million.

Via Benzinga

Here's Why Theravance Biopharma Shares Are Moving ↗

September 19, 2022

Theravance Biopharma Inc (NASDAQ: TBPH) shares are trading higher by 2.78% to $10.35 Monday afternoon after the company authorized a $250 million capital return program. What Else?

Via Benzinga

Theravance Outlines $250M Capital Return Program; To Repurchase GSK's Entire Holdings ↗

September 19, 2022

Via Benzinga

Looking Into Theravance Biopharma's Return On Capital Employed ↗

August 24, 2022

According to data from Benzinga Pro, during Q2, Theravance Biopharma's (NASDAQ:TBPH) reported sales totaled $11.05 million. Despite a 68.43% increase in earnings, the company posted a loss of $8.19...

Via Benzinga

Theravance Biopharma's Earnings: A Preview ↗

August 03, 2022

Theravance Biopharma (NASDAQ:TBPH) is set to give its latest quarterly earnings report on Thursday, 2022-08-04. Here's what investors need to know before the announcement. Analysts estimate that...

Via Benzinga

Why Is Conagra Brands Dropping By More Than 8%? 43 Stocks Moving In Thursday's Mid-Day Session ↗

July 14, 2022

Gainers Shineco, Inc. (NASDAQ: SISI) shares climbed 24.5% to $1.2201 on heavy volume.

Via Benzinga

The Daily Biotech Pulse: Much Awaited FDA Nod For Novavax's COVID-19 Shot, DSMB Suggests ContraFect To Stop Antimicrobial-Resistant Infection Study, CytomX Restructures ↗

July 14, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

< Previous 1 2 3 4 5 6 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.